Proactiveinvestors recommends

Red Sky Energy sees upside potential as New South Wales decision on Talma CSG pilot draws near
Xceed Resources: Cash backed and developing coal production and cash flows from Moabsvelden
Oro Verde on the exploration trail of gold and copper in Chile, commences trading today

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	IPD
Latest Price:	0.56 (1.82% )
52-week High:	0.84
52-week Low:	0.44
Market Cap:	87.52M

1 year chart

1 day chart

ImpediMed
ImpediMed is a global company with offices in Australia, the USA, and the UK. We develop bioimpedance devices with a focus on medical applications for use in a variety of healthcare segments that are non-invasive, compact and portable, highly accurate, fast, simple to operate, and considerably cheaper than most existing alternatives.

These products have a wide range of potential commercial applications, notably in the assessment and monitoring of secondary lymphedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring and sports medicine and fitness. The company is pioneering the use of next generation bioimpedance technology both in BIS (Bioimpedance Spectroscopy) and BIA (Bioimpedance Analysis).

More kudos for ImpediMed BIS device for early detection of lymphedema

Tuesday, November 24, 2009

A University of Sydney study has found that ImpediMed's (ASX: IPD) Bioimpedance Spectroscopy (BIS) device is the most suitable for early detection and monitoring of lymphedema.

The share price of ImpediMed moved higher to $0.85 on the news.

The study's findings by researchers at the University of Sydney‟s Breast Cancer Research Group were published this month in the journal Cancer Investigation - found that "BIS is the only measurement method specific to extracellular fluid, ideally suited for early detection and monitoring of lymphedema."

ImpediMed CEO Greg Brown said "this latest study adds weight to the debate presently being held around the globe about the need for standardised objective metrics driving evidence based medicine."

"ImpediMed is very focussed on changing the care model for lymphoedema management in cancer patients from a reactive to a prospective one, he said."

"If lymphoedema can be detected early, progression to the irreversible stages of the condition may be prevented, affording the patient a far better quality of life. We are pleased to be able to offer our L-Dex® U400 device to clinicians to aid them in the early clinical assessment of lymphoedema."

The study was a comparison of physical measurement methods and self report in the assessment of breast cancer-related arm lymphoedema.

It observed that the results from physical measurement methods other than BIS may be confounded by changes not related to lymphoedema such as muscle and fat. Therefore, early lymphoedema build up may go undetected when using these measurement methods.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.